Diabetes Cluster Group

1
Diabetes Cluster Group

• Co-chairs
• Holly Divine, Pharm.D., CGP, CDE -
• Associate Professor, University of Kentucky
  College of Pharmacy
• David Medvedeff, Pharm.D., MBA - CEO,
  Avatar International

2
Diabetes Cluster Group

• Group Members
• Dawn Blank, RPh., CDE Eli Lilly
• Abby Caplan Kerr Drug
• James Caro, RPh., MBA Sanofi-Aventis
• Pat Carroll-Grant
• Vicky Chan Novo Nordisk
• Kevin Cleary Medco
• Christina Ellegood Cardinal Health
• Chris Lamer
• Nancy Lyons, CDE, CDM Supervalu
• Jeanne Manzi, Pharm.D., CGP Innovatix
• Mike Sherry CVS
• Sunil Sinha, MD, MBA Pfizer
• Peggy Soule-Odegard, Pharm.D., BCPS, CDE Univ.
  of Wash.
• Veronica Tomor Pharm.D. Novo Nordisk
• Celia West - ARNP

3
Measure Concepts

• Appropriate Monitoring Labs (A1c)
• Appropriate Monitoring Labs (Urine Microalbumin)
• Appropriate Monitoring Labs (LDL-C)

4
Appropriate Monitoring Labs (A1c)
Glucose control measures may move from A1c to
estimated average glucose (EAG).
5
Appropriate Monitoring Labs (Urine
Microalbumin)
Urine microalbumin screens may be reported as
urine albumin/creatinine (UA/Cr) ratios.
6
Appropriate Monitoring Labs (LDL-C)